The GEOMETRY mono-1 trial reported a 68% response rate with capmatinib for untreated patients whose NSCLC contained MET exon 14 skipping mutations with a 12.6-month median duration of response. The gene discussed is MET; the disease is non-small cell lung carcinoma.